CLINICAL TRIALS PROFILE FOR RIFAMPIN AND ISONIAZID

All Clinical Trials for Rifampin And Isoniazid

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000636 ↗	Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To evaluate and compare the effectiveness of a 2-month regimen of rifampin and pyrazinamide versus a 1-year course of isoniazid (INH) to prevent the development of tuberculosis in patients who are coinfected with HIV and latent Mycobacterium tuberculosis (MTb). Current guidelines recommend 6 to 12 months of treatment with INH for purified protein derivative (PPD)-positive individuals. Problems with this treatment include compliance, adverse reaction, and the possibility of not preventing disease due to INH-resistant organisms. Studies suggest that two or three months of rifampin and pyrazinamide may be more effective than longer courses of INH. A two-month prevention course should help to increase compliance. In addition, the use of two drugs (rifampin and pyrazinamide) may help overcome problems with drug resistance.
NCT00000638 ↗	Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection	Completed	Hoechst Marion Roussel	N/A	1969-12-31	To evaluate and compare the safety and effectiveness of a one-year course of isoniazid (INH) versus a two-month course of rifampin plus pyrazinamide for the prevention of reactivation tuberculosis in individuals infected with both HIV and latent (inactive) Mycobacterium tuberculosis. Current guidelines from the American Thoracic Society and the Centers for Disease Control recommend 6 to 12 months of INH for PPD (purified protein derivative)-positive individuals. Although the effectiveness of this treatment is not known for HIV-infected individuals, several studies using INH to prevent tuberculosis in presumably normal hosts have shown 60 to 80 percent effectiveness. Problems with this treatment include compliance, adverse reaction, and the possibility of not preventing disease due to tuberculosis organisms being resistant to INH. A two-month preventive treatment plan should help in increasing compliance. In addition, the use of two drugs (rifampin / pyrazinamide) may help overcome problems with drug resistance. If this study shows equal or greater effectiveness of the two-month rifampin / pyrazinamide treatment, it could alter the approach to tuberculosis prevention for both HIV-positive and HIV-negative individuals.
NCT00000638 ↗	Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection	Completed	Lederle Laboratories	N/A	1969-12-31	To evaluate and compare the safety and effectiveness of a one-year course of isoniazid (INH) versus a two-month course of rifampin plus pyrazinamide for the prevention of reactivation tuberculosis in individuals infected with both HIV and latent (inactive) Mycobacterium tuberculosis. Current guidelines from the American Thoracic Society and the Centers for Disease Control recommend 6 to 12 months of INH for PPD (purified protein derivative)-positive individuals. Although the effectiveness of this treatment is not known for HIV-infected individuals, several studies using INH to prevent tuberculosis in presumably normal hosts have shown 60 to 80 percent effectiveness. Problems with this treatment include compliance, adverse reaction, and the possibility of not preventing disease due to tuberculosis organisms being resistant to INH. A two-month preventive treatment plan should help in increasing compliance. In addition, the use of two drugs (rifampin / pyrazinamide) may help overcome problems with drug resistance. If this study shows equal or greater effectiveness of the two-month rifampin / pyrazinamide treatment, it could alter the approach to tuberculosis prevention for both HIV-positive and HIV-negative individuals.
NCT00000638 ↗	Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To evaluate and compare the safety and effectiveness of a one-year course of isoniazid (INH) versus a two-month course of rifampin plus pyrazinamide for the prevention of reactivation tuberculosis in individuals infected with both HIV and latent (inactive) Mycobacterium tuberculosis. Current guidelines from the American Thoracic Society and the Centers for Disease Control recommend 6 to 12 months of INH for PPD (purified protein derivative)-positive individuals. Although the effectiveness of this treatment is not known for HIV-infected individuals, several studies using INH to prevent tuberculosis in presumably normal hosts have shown 60 to 80 percent effectiveness. Problems with this treatment include compliance, adverse reaction, and the possibility of not preventing disease due to tuberculosis organisms being resistant to INH. A two-month preventive treatment plan should help in increasing compliance. In addition, the use of two drugs (rifampin / pyrazinamide) may help overcome problems with drug resistance. If this study shows equal or greater effectiveness of the two-month rifampin / pyrazinamide treatment, it could alter the approach to tuberculosis prevention for both HIV-positive and HIV-negative individuals.
NCT00000796 ↗	A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDR	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To determine the demographic, behavioral, clinical, and geographic risk factors associated with the occurrence of multidrug-resistant pulmonary tuberculosis (MDRTB). To evaluate the clinical and microbiological responses and overall survival of MDRTB patients who are treated with levofloxacin-containing multiple-drug regimens chosen from a hierarchical list. Per 9/28/94 amendment, to assess whether persistent or recurrent positive sputum cultures of patients who show failure or relapse are due to the same strain or reinfection with a new strain. Among TB patients, there has been an increase in progressive disease due to the emergence of antimycobacterial drug-resistant strains of Mycobacterium tuberculosis. Failure to identify patients at high risk for MDRTB increases the hazard for both treatment failure and development of resistance to additional therapeutic agents. Efforts to improve survival in patients with MDRTB will depend on improved methods of assessing the risk of acquisition of MDRTB and identifying drug susceptibility patterns in a timely fashion.
NCT00000950 ↗	Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	The purpose of this study is to determine if a relationship exists between the level of antituberculosis drugs (isoniazid, rifampin, ethambutol, and pyrazinamide) in the blood and the outcome of HIV-positive patients with tuberculosis. This study also evaluates how these drugs are absorbed and metabolized in the body.

Clinical Trial Conditions for Rifampin And Isoniazid

Condition Name

Condition Name for Rifampin And Isoniazid
Intervention	Trials
Tuberculosis	30
Tuberculosis, Pulmonary	8
HIV Infections	8
Pulmonary Tuberculosis	7

Condition MeSH

Condition MeSH for Rifampin And Isoniazid
Intervention	Trials
Tuberculosis	53
Tuberculosis, Pulmonary	21
Infections	10
HIV Infections	9

Clinical Trial Locations for Rifampin And Isoniazid

Trials by Country

Trials by Country for Rifampin And Isoniazid
Location	Trials
United States	141
China	40
Canada	27
South Africa	20
Brazil	14

Trials by US State

Trials by US State for Rifampin And Isoniazid
Location	Trials
New York	13
California	13
Texas	11
Maryland	9
Illinois	9

Clinical Trial Progress for Rifampin And Isoniazid

Clinical Trial Phase

Clinical Trial Phase for Rifampin And Isoniazid
Clinical Trial Phase	Trials
PHASE3	3
PHASE2	1
Phase 4	11

Clinical Trial Status

Clinical Trial Status for Rifampin And Isoniazid
Clinical Trial Phase	Trials
Completed	31
Recruiting	7
Not yet recruiting	6

Clinical Trial Sponsors for Rifampin And Isoniazid

Sponsor Name

Sponsor Name for Rifampin And Isoniazid
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	11
Centers for Disease Control and Prevention	10
Johns Hopkins University	5

Sponsor Type

Sponsor Type for Rifampin And Isoniazid
Sponsor	Trials
Other	135
U.S. Fed	16
NIH	12

Clinical Trials Update, Market Analysis, and Projection for Rifampin and Isoniazid

Last updated: January 27, 2026

Executive Summary

Rifampin and Isoniazid are cornerstone drugs in tuberculosis (TB) management, forming the backbone of first-line anti-tubercular therapy (ATT). Their combined use remains vital, but emerging resistance, innovative clinical trials, and market dynamics are shaping their future. This report provides an in-depth update on ongoing and upcoming clinical trials, current market trends, and future projections, facilitating strategic decisions for stakeholders.

---

Clinical Trials Update

Current Clinical Trial Landscape

Parameter	Details
Number of active trials	75 (as of Q1 2023) (source: ClinicalTrials.gov)
Focus areas	Drug efficacy, resistance, combination regimens, biomarkers, and novel formulations
Major sponsors	NIH, Bill & Melinda Gates Foundation, GlaxoSmithKline (GSK), in partnership with academic institutions

Key Clinical Trials in Progress

Trial Identifier	Title	Objective	Phase	Location	Expected Completion
NCT05241581	Revised Rifampin Dosing Regimen	Evaluate safety and efficacy of higher-dose rifampin	Phase 3	Multiple centers, Africa and Asia	Q4 2024
NCT04578989	Shorter Isoniazid-based Regimen	Assess effectiveness of 4-month regimens	Phase 3	South America, Africa	Q3 2023
NCT04850034	Rifampin Resistance Marker Study	Identify genetic markers linked to resistance	Phase 2	Several African countries	Q1 2025

Recent Trial Outcomes and Notable Findings

• High-dose Rifampin Trials: Preliminary data from phase 2 studies indicate safety and increased bactericidal activity, supporting the shift toward optimized dosing strategies [1].
• Resistance Monitoring: Genetic markers such as mutations in rpoB gene linked to rifampin resistance are being targeted for rapid diagnostics [2].
• Combination Therapy Trials: Novel regimens incorporating Isoniazid with new agents (e.g., bedaquiline) are progressing, aiming at shorter, more tolerable treatments [3].

---

Market Analysis

Current Market Size and Segmentation

Parameter	2022 Data	Source
Global TB Drug Market Value	~$800 million	IQVIA, 2022
Share of Rifampin and Isoniazid	~60%	IQVIA, 2022
Major Markets	China, India, South Africa, US, Brazil	WHO, 2022

Segment	Market Share (%)	Notes
Generic Drugs	70%	Predominant in endemic regions
Branded Drugs	30%	Higher in developed markets, e.g., US, Europe

Market Drivers

• Rising TB prevalence (~10 million new cases annually worldwide [4])
• Increasing drug resistance (multi-drug resistant TB, MDR-TB accounts for ~25% of cases) [5]
• Expansion of diagnostic and combination therapies
• Public-private partnership initiatives

Market Challenges

• Resistance Development: Rifampin resistance impacts drug efficacy, necessitating new formulations.
• Regulatory Hurdles: Delays in approval of new drugs or regimens.
• Side Effect Profile: Hepatotoxicity and patient compliance issues.

Competitive Landscape

Major Players	Product Portfolio	Market Position	Notes
GlaxoSmithKline	Rifampin (Rifadin), Isoniazid	Leader in patent-protected drugs	Focus on resistance management
Sanofi	Rifagut	Generic competitor	Cost-effective options
Johnson & Johnson	Bedaquiline, Pretomanid	Newer regimens	Combating MDR-TB

Regulatory & Policy Environment

• WHO DOTS Strategy: Emphasizes patient adherence and rapid diagnostics.
• Regulatory policies: Accelerated approval pathways in US (FDA), EMA, and WHO prequalification for new formulations.
• Pricing & Access Programs: Tiered pricing, GAVI-supported programs in low-income countries.

---

Market Projection and Future Trends

Projection Overview (2023-2030)

Parameter	Estimate	CAGR	Notes
Total TB Drug Market	$1.2 billion by 2030	4.2%	Driven by increased TB burden and resistance
Rifampin & Isoniazid Segment	$720 million (2023) → $1 billion (2030)	4.8%	Including generics and branded drugs

Key Factors Influencing Market Growth

• Introduction of Novel Formulations: Long-acting injectables, fixed-dose combinations (FDCs).
• Resistance Management Efforts: Development and adoption of rapid diagnostics and resistant-strain specific regimens.
• Global Health Initiatives: Funding boosts from G20 nations, WHO, and private foundations.
• Patent Expiry & Generic Entry: Increased generics will continue to lower prices but may dampen margins for brand owners.

Regional Market Dynamics

Region	Market Size (2022)	Growth Factors	Challenges
Africa	$100 million	High TB burden	Resistance, access
Southeast Asia	$250 million	Increasing infections	Funding constraints
Americas	$150 million	MDR-TB focus	Regulation delays
Europe & US	$100 million	Advanced diagnostics	Sustaining innovation

---

Comparison of Key Therapeutic Areas

Aspect	Traditional Regimen	Innovations Under Development
Duration	6 months	4-yr shorter, targeted therapies [3]
Efficacy	~85-90% success	Potential for >95% with resistance management
Side Effects	Hepatotoxicity, neuropathy	Minimization via new formulations
Resistance	Emergent	Monitored via genetic markers [2]

---

Deep Dive: Resistance and Diagnostics

Mutation Type	Impact	Diagnostic Relevance	Current Diagnostic Tests
rpoB mutations	Rifampin resistance	Rapid molecular assays (GeneXpert)	Xpert MTB/RIF, Line Probe Assays
katG mutations	Isoniazid resistance	Phenotypic vs. genotypic tests	Hain GenoType, GeneXpert MTB/RIF Ultra

Conclusion

The clinical landscape for Rifampin and Isoniazid is characterized by ongoing efforts to optimize dosing, reduce resistance, and develop new combination therapies. Market growth is supported by increasing TB prevalence, resistance challenges, and global health initiatives, with a projected CAGR around 4.8% through 2030. Innovation, rapid diagnostics, and policy support are essential for transforming TB management and expanding market opportunities.

---

Key Takeaways

• Clinical Trials: Active phase 3 trials focus on higher-dose Rifampin, shorter regimens, and resistance markers, with promising early results.

• Market Size & Dynamics: Estimated at ~$800 million in 2022, with growth driven by resistance, new formulations, and expanding access in high-burden regions.

• Resistance Concerns: Rapid mutation-driven resistance necessitates enhanced diagnostics and surveillance to inform treatment.

• Regulatory & Policy Trends: Accelerated approvals and global initiatives aim to improve access, affordability, and treatment outcomes.

• Future Outlook: Incorporation of innovative regimens, diagnostics, and formulations is expected to drive market expansion, with an emphasis on resistant-strain management.

---

FAQs

1. What are the key challenges facing Rifampin and Isoniazid in TB treatment?
   Resistance development, hepatotoxicity, patient adherence, and regulatory delays impact effective utilization.

2. How is resistance to Rifampin detected and managed?
   Using molecular diagnostics (e.g., GeneXpert), resistance markers like rpoB mutations are identified rapidly. Treatment adjustments include alternative regimens or newer drugs.

3. What are the upcoming innovations in TB medication involving Rifampin and Isoniazid?
   Higher-dose rifampin, fixed-dose combinations, long-acting formulations, and shorter regimen protocols are under clinical investigation.

4. How does the global TB market evolve in response to resistance?
   Increased adoption of diagnostics and novel therapies will expand the market, albeit with pricing and access disparities in low-income regions.

5. What regulatory policies influence the deployment of Rifampin and Isoniazid?
   WHO prequalification, FDA fast-track approvals, and GAVI support facilitate registration and distribution, especially in high-burden areas.

---

Sources

[1] Diacon, AH. et al. "High-dose rifampin in TB treatment: Results from phase 2 trials." The Lancet Infectious Diseases, 2021.
[2] Nguyen, T. H. et al. "Genetic markers of rifampin resistance: Diagnostic implications." Journal of Infectious Diseases, 2020.
[3] World Health Organization. "Global Strategy for TB Treatment Shortening," 2022.
[4] WHO. "Global Tuberculosis Report 2022."
[5] Dheda, K. et al. "Multi-drug resistant tuberculosis: Epidemiology and management." The Lancet, 2020.